Dr. Derrick D. Muse, M.D.
Family Medicine (Family Medicine Physician)
4460 Highland Dr Ste 400
Salt Lake City, UT 84124
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 12
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
NV license 29544 · UT license 181302-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 12
- Services billed
- 26
- Patients’ average age
- 69
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Salt Lake City, UT | 299 |
| Rosuvastatin Calcium Other prescribers in Salt Lake City, UT | 190 |
| Levothyroxine Sodium Other prescribers in Salt Lake City, UT | 179 |
| Oxycodone Hcl Other prescribers in Salt Lake City, UT | 159 |
| Omeprazole Other prescribers in Salt Lake City, UT | 136 |
| Ezetimibe Other prescribers in Salt Lake City, UT | 135 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Salt Lake City, UT | 124 |
| Amlodipine Besylate Other prescribers in Salt Lake City, UT | 108 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Salt Lake City, UT | 101 |
| Metformin Hcl Er (metformin hcl) Other prescribers in Salt Lake City, UT | 98 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 51 payments worth $2,386 in total to this clinician.
| Merck Sharp & Dohme LLC | $1,694 |
|---|---|
| AbbVie Inc. | $198 |
| Medtronic, Inc. | $51.93 |
| Amgen Inc. | $51.83 |
| Lilly USA, LLC | $51.43 |
| Pfizer Inc. | $48.06 |
| Vertex Pharmaceuticals Incorporated | $39.74 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.63 |
| Travel and Lodging | $1,400 |
|---|---|
| Food and Beverage | $986 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $801 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $238 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $126 |
| Merck Sharp & Dohme LLC Oct 6, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA Company’s descriptionProvided as part of a clinical research engagement. | $99.18 |
| Merck Sharp & Dohme LLC Sep 23, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Atlanta, GA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $97.70 |
| Merck Sharp & Dohme LLC Feb 6, 2025 | Travel and Lodging CARDIOVASCULAR · travel to Dallas, TX Company’s descriptionProvided as part of a clinical research engagement. | $38.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $59,837 in research payments for these studies, mostly to the institutions running them.
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.